Dynamic BH3 Profiling Predicts Patient Response and MRD Status in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Frontline Treatment with Kinase Inhibitor Plus FCR (KI+FCR)
Year: 2018
Type: conference-abstract
Source: Blood
Institution: Dana-Farber Cancer Institute
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2912814154